PTC Therapeutics, Inc.

NasdaqGS:PTCT Stock Report

Market Cap: US$5.5b

PTC Therapeutics Valuation

Is PTCT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PTCT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: PTCT ($66.06) is trading below our estimate of future cash flow value ($222.96)

Significantly Below Future Cash Flow Value: PTCT is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PTCT?

Key metric: As PTCT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PTCT. This is calculated by dividing PTCT's market cap by their current revenue.
What is PTCT's PS Ratio?
PS Ratio5.5x
SalesUS$1.01b
Market CapUS$5.51b

Price to Sales Ratio vs Peers

How does PTCT's PS Ratio compare to its peers?

The above table shows the PS ratio for PTCT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average15.6x
ACAD ACADIA Pharmaceuticals
4.2x10.82%US$4.8b
TWST Twist Bioscience
18.5x17.07%US$8.0b
VCYT Veracyte
5.8x11.21%US$3.4b
PTGX Protagonist Therapeutics
34x17.02%US$9.4b
PTCT PTC Therapeutics
5.5x13.61%US$5.5b

Price-To-Sales vs Peers: PTCT is good value based on its Price-To-Sales Ratio (5.5x) compared to the peer average (15.6x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does PTCT's PS Ratio compare vs other companies in the US Biotechs Industry?

122 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
3.2x2.60%US$31.83b
BMRN BioMarin Pharmaceutical
3.7x10.33%US$12.68b
LEGN Legend Biotech
2.8x15.48%US$3.72b
SRPT Sarepta Therapeutics
1.1x-11.00%US$2.17b
PTCT 5.5xIndustry Avg. 12.7xNo. of Companies122PS01632486480+
122 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: PTCT is good value based on its Price-To-Sales Ratio (5.5x) compared to the US Biotechs industry average (12.7x).

Price to Sales Ratio vs Fair Ratio

What is PTCT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PTCT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.5x
Fair PS Ratio4.8x

Price-To-Sales vs Fair Ratio: PTCT is expensive based on its Price-To-Sales Ratio (5.5x) compared to the estimated Fair Price-To-Sales Ratio (4.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PTCT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$66.06
US$99.29
+50.30%
17.26%US$130.00US$70.00n/a14
Sep ’27US$70.56
US$99.29
+40.71%
17.26%US$130.00US$70.00n/a14
Aug ’27US$68.01
US$97.86
+43.89%
16.62%US$130.00US$70.00n/a14
Jul ’27US$81.35
US$93.93
+15.46%
17.21%US$124.00US$65.00n/a14
Jun ’27US$73.80
US$91.57
+24.08%
17.85%US$124.00US$65.00n/a14
May ’27US$65.15
US$88.07
+35.18%
19.42%US$124.00US$61.00n/a15
Apr ’27US$68.75
US$86.50
+25.82%
19.65%US$124.00US$60.00n/a14
Mar ’27US$68.19
US$87.57
+28.42%
19.15%US$124.00US$60.00n/a14
Feb ’27US$75.53
US$88.50
+17.17%
18.87%US$124.00US$60.00n/a14
Jan ’27US$75.96
US$81.86
+7.76%
19.94%US$118.00US$55.00n/a14
Dec ’26US$79.20
US$81.14
+2.45%
20.70%US$118.00US$50.00n/a14
Nov ’26US$68.31
US$67.93
-0.55%
27.88%US$118.00US$44.00n/a15
Oct ’26US$62.01
US$66.69
+7.54%
26.94%US$118.00US$44.00n/a16
Sep ’26US$49.33
US$66.69
+35.19%
26.94%US$118.00US$44.00US$70.5616
Aug ’26US$52.13
US$67.38
+29.24%
28.15%US$120.00US$44.00US$68.0116
Jul ’26US$48.59
US$62.81
+29.27%
27.86%US$112.00US$40.00US$81.3516
Jun ’26US$48.52
US$61.53
+26.82%
28.45%US$112.00US$40.00US$73.8015
May ’26US$49.52
US$64.79
+30.83%
25.20%US$113.00US$40.00US$65.1514
Apr ’26US$46.60
US$64.71
+38.87%
25.10%US$113.00US$42.00US$68.7514
Mar ’26US$55.26
US$63.00
+14.01%
27.42%US$113.00US$41.00US$68.1914
Feb ’26US$45.88
US$58.14
+26.73%
23.22%US$76.00US$32.00US$75.5314
Jan ’26US$45.14
US$58.71
+30.07%
23.66%US$80.00US$32.00US$75.9614
Dec ’25US$43.88
US$46.14
+5.16%
27.35%US$68.00US$26.00US$79.2014
Nov ’25US$40.47
US$41.50
+2.55%
26.30%US$64.00US$26.00US$68.3114
Oct ’25US$36.05
US$39.71
+10.16%
27.72%US$64.00US$26.00US$62.0114
Sep ’25US$35.32
US$39.38
+11.51%
28.84%US$64.00US$26.00US$49.3313
US$99.29
Fair Value
33.5% undervalued intrinsic discount
14
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/12 01:48
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PTC Therapeutics, Inc. is covered by 33 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Luke HerrmannBaird
null nullBaird